Drugs / LAM-002A
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02594384 | Oct 2015 → Mar 2020 | lymphoid neoplasm | OrphAI Therapeutics | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05163886 | Dec 2021 → Jan 2023 | amyotrophic lateral sclerosis | OrphAI Therapeutics | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT05483322 | — | frontotemporal dementia | OrphAI Therapeutics | No longer available | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LAM-002A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05483322 ↗ |
| Action | Inhibit | “PIKfyve inhibitor” PMID 38606777 ↗ Sep 2024 |
| Route | Oral | “administered by mouth” NCT02594384 ↗ |
| Target | PIKFYVE | “PIKfyve inhibitor” PMID 38606777 ↗ Sep 2024 |